Date post: | 23-Dec-2015 |
Category: |
Documents |
Upload: | muriel-elliott |
View: | 219 times |
Download: | 0 times |
OIC-SHPA 2014-2023 & Vaccines Need Assessmentin OIC Member Countries
STATISTICAL, ECONOMIC AND SOCIAL RESEARCH AND TRAINING CENTRE FOR ISLAMIC COUNTRIES
ORGANIZATION OF ISLAMIC COOPERATION
Prof. Savas AlpayDirector General
OIC-SHPA 2014-2023
3
OIC-SHPA aims to strengthen health care delivery system and improve health situation in OIC member countries especially by facilitating and promoting intra-OIC transfer of knowledge and expertise
OIC-SHPA is a framework of cooperation among OIC member countries, relevant OIC institutions and international organizations in the domain of health
SESRIC lead the preparation of OIC-SHPA and its Implementation Plan in collaboration with OIC member countries and Institutions and International Health organizations;
SIX Thematic Areas of Cooperation
4
Health System Strengthening
Disease Prevention and Control
Maternal, New-born and Child Health and Nutrition
Medicine, Vaccine and Medical Technologies
Emergency Health Response and Interventions
Information, Education, Research and Advocacy
2
3
4
5
6
1
5
Implementation Plan of the OIC-SHPA
Implementation Plan is based on OIC-SHPA findings and describes actions/activities under each TA with:
i- Timeline for their implementation (short, medium and long term)
ii- Key Performance Indicators (KPIs) to monitor the implementation
iii- Implementing partners (both national and international institutions)
Thematic area 4: Medicine, Vaccine and Medical Technologies
6
2
3
4
5
6
1• focuses at medicines and vaccines manufacturing,
monitoring and evaluation mechanisms and promotion of research and development (R&D) and innovation.
• proposes four programmes of action with several actions and activities:
PA–1 Enhancing Monitoring and Evaluation Mechanisms
PA–2 Supporting Local Production of Medicine and Vaccines
PA–3 Promoting Research and Development (R&D) in Health-related fields
PA–4 Increasing the Availability of Essential Medicines, Vaccines and Technologies
Thematic area 4: Medicine, Vaccine and Medical Technologies
7
2
3
4
5
6
1Some selected activities from Implementation Plan:• Facilitating training among member countries through sharing of
knowledge and expertise for the development and strengthening of pharmacovigilance system
• Improving investment climate by simplifying the requirements for doing business in pharmaceutical and other medical products industry
• Establishing an intersectoral intra-OIC committee of experts on local production
• Providing material and technical assistance to develop national guidelines related to distribution of vaccines
• Facilitating development of OIC regional pooled procurement mechanism which will enable local production to meet regional needs and allow for the mutual cooperation in increasing the availability of essential medicines and vaccines
9
Vaccines and Immunization• Childhood immunization is one of the most efficient and
effective methods of preventing diseases like Measles, Meningitis, Diphtheria, Tetanus, Pertussis (whooping cough), Yellow fever, Polio and Hepatitis B.
• Immunization is an essential component for reducing under-five mortality.
• Immunization coverage estimates are used to monitor coverage of immunization services and to guide disease eradication and elimination efforts.
• It is a good indicator of health system performance.
10
WHO Recommended Immunization Schedule
Age of Contact Vaccine
Birth BCG, OPV-0, Hep B
6 weeks OPV1, Penta1 (DTP, Hep B*, Hib)
10 weeks OPV2, Penta2 (DTP, Hep B*, Hib)
14 weeks OPV3, penta3 (DTP, Hep B*, Hib)
9 months Measles, Hep B*, YF
12-15 months Measles 2nd dose and Rubella
11
DTP3 Immunization Coverage: 3rd dose of Diphtheria-Tetanus-Pertussis (2012)
OIC Countries 83
Other Developing 85
Developed 95
World 83
OIC Regions SSA 73 SA 87 MENA 91 ECA 94 EAP 84 LAC 92
12
MCV: Measles Immunization Coverage (2012)
OIC Countries 81 Other Developing 85 Developed 92 World 84
OIC Regions SSA 53 SA 80 MENA 89 ECA 91 EAP 78 LAC 92
13
Polio Immunization Coverage (2012) OIC Countries 75 Other Developing 83 Developed 97 World 84
OIC Regions SSA 75 SA 83 MENA 93 ECA 95 EAP 74
LAC 95
14
Vaccines Need Assessment: Country Coverage
SSA 19 SA 3 MENA 2 ECA 5 EAP 1 LAC 1
Data acquired from GAVI Alliance.. covers only 31 MCs (colored dark red) with following regional distribution:
15
Penta Vaccine ‘five-in-one’..for Diphtheria, Tetanus, Whooping cough, Hepatitis B and Haemophilus influenzae type b (Hib)
2011
2012
2013
2014
2015
25,828,910.0
26,447,447.0
28,165,916.0
29,629,915.0
30,890,913.0
Children to be Vaccinated(millions)
2011
2012
2013
2014
2015
77,486,730.0
79,342,341.0
84,497,748.0
88,889,745.0
92,672,739.0
Dose Needed (mil-lions)
2011
2012
2013
2014
2015
12,397,876.8
12,694,774.6
13,519,639.7
14,222,359.2
14,827,638.2
US$ million
DTP3 (for Diphtheria-Tetanus-Pertussis)
16
2011
2012
2013
2014
2015
23000000
24000000
25000000
26000000
27000000
28000000
29000000
30000000
31000000
32000000
28,178,704.0
29,459,967.0
26,331,088.0
29,698,225.0
31,011,464.0
Dose Neededmillion
2011
2012
2013
2014
2015
198,659.86
207,692.77
185,634.17
209,372.49
218,630.82
US$ million
2011
2012
2013
2014
2015
28,178,704.0
29,459,967.0
26,331,088.0
29,698,225.0
31,011,464.0
Children to be Vaccinated (mil-
lions)
17
OPV3 (for Polio)20
11
2012
2013
2014
2015
28,008,702.0
29,274,825.0
30,575,032.0
31,869,876.0
33,189,063.0
Children to be Vaccinated (mil-
lions)
2011
2012
2013
2014
2015
28,008,702.0
29,274,825.0
30,575,032.0
31,869,876.0
33,189,063.0
Dose Needed (mil-lions)
2011
2012
2013
2014
2015
165,391.39
172,867.84
180,545.56
188,191.62
195,981.42
US$ million
18
MCV (for Measles)20
11
2012
2013
2014
2015
28,008,702.0
29,274,825.0
30,575,032.0
31,869,876.0
33,189,063.0
Children to be Vaccinated (mil-
lions)
2011
2012
2013
2014
2015
27,636,632.0
29,019,249.0
29,545,785.0
29,519,865.0
31,068,251.0
Dose Needed (mil-lions)
2011
2012
2013
2014
2015
5,333,869.98
5,600,715.06
5,702,336.51
5,697,333.95
5,996,172.44
US$ million
19
Tetanus
2011
2012
2013
2014
2015
29,812,774.0
32,551,704.0
34,485,710.0
36,212,326.0
37,842,881.0
Dose Needed (mil-lions)
2011
2012
2013
2014
2015
43,973.84
48,013.76
50,866.42
53,413.18
55,818.25
US$ million
2011
2012
2013
2014
2015
29,812,774.0
32,551,704.0
34,485,710.0
36,212,326.0
37,842,881.0
Children to be Vaccinated (mil-
lions)
20
BCG (for Tuberculosis)20
11
2012
2013
2014
2015
30,809,897.0
32,132,391.0
33,276,311.0
34,581,444.0
35,953,897.0
Children to be Vaccinated (mil-
lions)
2011
2012
2013
2014
2015
30,809,897.0
32,132,391.0
33,276,311.0
34,581,444.0
35,953,897.0
Dose Needed (millions)
2011
2012
2013
2014
2015
87,808.21
91,577.31
94,837.49
98,557.12
102,468.61
US$ million
Current Stance of Vaccine Supply
• OIC countries display heterogeneous structure in terms of being able to uptake new vaccines.– Low income countries obtain vaccines mostly
through GAVI Alliance.– Middle income countries have been
experiencing financial and operational difficulties with the introduction of new vaccines. They have the following obstacles:• Lack of sufficient funds• Prevailing high prices of vaccines
– High income countries such as GCC have been successful in the uptake of new vaccines. 21
22
Current Stance of Vaccine Distribution
• The purchase of vaccines is complex and requires a specialized knowledge and a precise approach.
• Due to the specificities of the vaccines, quality, safety and efficacy should be the first considerations to be taking into account.
• Cold chain conditions should be respected during shipment and cold room capacity should be available at the time of the receipt of the vaccines.
• There are many companies producing vaccines but only a few meet internationally-recognized standards of safety and efficacy.
23
Exports of Vaccines for Human Use
OIC countries are still accounting for less than 1% of the total world vaccine exports.
OIC exports of vaccine recorded only 122.7 million USD in 2012.
2007 2008 2009 2010 2011 20120
100
200
300
400
500
600
700
0
1
2
3
4
5
6
11.9 15.9 11.7
134.887.3
122.763
161
518.2
375.9
578.6 560.3
OIC Non-OIC Developing OIC as % of World
Mill
ions
Perc
ent
24
Imports of Vaccines for Human Use
OIC countries accounted for 8% in total world vaccine imports in 2012.
OIC imports of vaccine recorded over 1.5 billionUSD in 2012 which is almost 13 times higher than their exports.
2007 2008 2009 2010 2011 20120.00.51.01.52.02.53.03.54.0
0123456789
0.250.66 0.69 0.86
1.191.53
0.85
2.04
3.01
3.72
3.07
3.65
OIC Non-OIC Developing OIC as % of World
Billi
ons
Perc
ent